[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"giant-cell-tumor-of-bone\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:giant-cell-tumor-of-bone":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,70,97,128,155,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640065","tracp-5b-for-diagnosis-and-follow-up-of-giant-cell-tumor-of-bone-100640065",false,"NCT07609277","TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone","TRACP-5b as a Novel Biomarker for the Diagnosis and Monitoring of Patients With Giant Cell Tumor of Bone","Inclusion Criteria:\n\n* Histologically confirmed Giant Cell Tumor of Bone\n* Newly diagnosed patients or patients undergoing long-term follow-up after previous treatment\n* Age ≥18 years\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Concurrent diseases significantly affecting bone metabolism, including metabolic bone disorders\n* Inability or unwillingness to provide informed consent\n* Patients unable to comply with routine follow-up procedures\n* Active conditions that may substantially influence serum TRACP-5b levels independently of Giant Cell Tumor of Bone evaluation","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","24 Months","OBSERVATIONAL","This prospective observational study will evaluate whether the blood biomarker TRACP-5b can help diagnose and monitor patients with giant cell tumor of bone (GCTB). GCTB is a rare but locally aggressive bone tumor that can return even after surgical treatment. Currently, patients require long-term follow-up based mainly on imaging examinations such as CT or MRI, and suspected recurrence often requires invasive biopsy procedures.\n\nTRACP-5b is an enzyme associated with osteoclast activity that can be measured from a blood sample. Previous studies suggest that TRACP-5b levels may reflect disease activity and risk of recurrence in patients with GCTB. In this study, patients with newly diagnosed GCTB and patients already undergoing long-term follow-up after treatment will undergo regular blood sampling for TRACP-5b measurement during routine outpatient visits. Laboratory results will be compared with the patient's clinical condition, imaging findings, and histological results when available.\n\nThe goal of the study is to determine whether TRACP-5b could become a reliable and minimally invasive tool for earlier detection of disease recurrence and improved long-term monitoring of patients with giant cell tumor of bone.",[25,26,27,28],"Giant Cell Tumor of Bone","TRACP-5b","Disease Surveillance and Monitoring","Tartrate-Resistant Acid Phosphatase 5b",[25,28,30,31],"Bone Tumor Biomarker","Serum Biomarkers","RECRUITING","2026-05-19",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":36},"2026-01-01",{"date":40,"type":20},"2028-05-31",{"name":42,"class":43},"St. Anne's University Hospital Brno, Czech Republic","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100308490","phase-3-local-bisphosphonate-effect-on-recurrence-rate-in-extremity-giant-cell-tumor-of-bone-100308490","NCT03295981","Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone","Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Primary benign GCT of bone\n* Lesion located in an extremity\n* Lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal\n* No previous systemic bisphosphonate or denosumab therapy\n\nExclusion Criteria:\n\n* Recurrent GCT of bone\n* Non-extremity location\n* Lesion too extensive for intralesional treatment, either due to bone loss, joint invasion, or large soft tissue component\n* Children and pregnancy\n* Previous systemic bisphosphonate or denosumab therapy",true,{"count":54,"type":20},120,"INTERVENTIONAL",[57],"PHASE3","The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.",[25],"2026-04-17",{"date":62,"type":36},"2026-04-22",{"date":64,"type":36},"2018-05-03",{"date":66,"type":20},"2028-01",{"name":68,"class":43},"St. Louis University",16,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":55,"phases":81,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100617223","phase-4-accuracy-of-indocyanine-green-icg-fluorescence-imaging-in-giant-cell-tumor-of-bone-surgery-100617223","NCT07315828","Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery","A Prospective Study on the Accuracy of Indocyanine Green Fluorescence Imaging for the Visualization of Residual Lesions in the Tumor Cavity During Surgery for Giant Cell Tumor of Bone","ICG-GCTB","Inclusion Criteria:\n\n* Diagnosed with Giant Cell Tumor of Bone(GCTB), via preoperative biopsy or typical imaging (MRI), and scheduled for surgical resection.\n* Capable of understanding the study and voluntarily signing the written informed consent form.\n\nExclusion Criteria:\n\n* Known severe history of allergy to Indocyanine Green (ICG) or iodine.\n* Severe liver dysfunction.\n* Women who are pregnant or lactating.","75 Years",{"count":80,"type":20},40,[82],"PHASE4","This study evaluates the diagnostic accuracy of Indocyanine Green (ICG) fluorescence imaging in visualizing residual lesions of Giant Cell Tumor of Bone (GCTB) in the tumor cavity during surgery. Patients diagnosed with GCTB will receive an intravenous injection of ICG prior to the operation to label tumor tissues. During the procedure, surgeons will use a near-infrared fluorescence imaging system to visualize the tumor cavity and identify potential residual lesions after standard curettage. The study aims to determine the sensitivity, specificity, positive predictive value, and negative predictive value of ICG fluorescence imaging by comparing the intraoperative fluorescence findings with the final pathological results of the validation samples.",[25],[86,87,88,25],"Indocyanine Green","Fluorescence Imaging","Near-Infrared Imaging","2026-01-02",{"date":91,"type":36},"2026-01-05",{"date":89,"type":36},{"date":94,"type":20},"2026-12",{"name":96,"class":43},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100610467","promis-and-mobility-evaluation-in-sarcoma-patients-100610467","NCT07227961","PROMIS and Mobility Evaluation in Sarcoma Patients","Evaluating the Implementation, Utility, and Clinical Importance of the Patient-Reported Outcome Measure Information System (PROMIS) in Sarcoma Patients: A Multi-Centered Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of bone sarcoma, soft tissue sarcoma, or giant cell tumor of bone\n* Tumors located in the pelvis, lower extremities, or upper extremities\n* Primary or recurrent disease\n* Undergoing operative tumor resection, including limb salvage surgery and amputation\n* Has an iPhone or Android phone\n* Speaks English\n\nExclusion Criteria:\n\n* Metastatic bone tumor\n* Diagnosis of atypical lipomatous tumor or dermatofibrosarcoma protuberans\n* Currently pregnant or planning pregnancy within 6 months\n* Unwilling or unable to attend follow-up evaluations\n* Cognitive or communication barriers that impede completion of questionnaires",{"count":105,"type":20},800,"The goal of this is to validate the Patient-Reported Outcomes Measurement Information System (PROMIS) in sarcoma patients undergoing surgery, and to evaluate a novel smartphone app for collecting mobility data. The goals of the study include to:\n\n1. Validate PROMIS as a patient outcome measure in sarcoma\n2. Assess the effectiveness of a novel app for administering questionnaires and collecting mobility metrics\n3. Compare PROMIS scores and mobility metrics to better evaluate recovery trajectories after surgery\n\nParticipants will complete PROMIS questionnaires at regularly scheduled intervals using the smartphone app. Questionnaires will be completed pre-operatively and at 6 weeks, 12 weeks, 6 months, and 12 months post-operatively. Additionally, the app will passively track mobility metrics such as daily step count, stairs climbed, and gait parameters to compare with PROMIS scores.",[108,25],"Sarcoma",[110,111,112,113,114,115,116,117,108],"Patient reported outcomes","PROMIS","TESS","Mobility","Recovery","Surgery","App","Digital health","2025-11-10",{"date":120,"type":36},"2025-11-13",{"date":122,"type":36},"2025-07-01",{"date":124,"type":20},"2031-01-01",{"name":126,"class":43},"University of Calgary",4,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":55,"phases":137,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":44},"100565878","phase-1-efficacy-of-icg-based-nir-imaging-in-intralesional-curettage-of-giant-cell-tumors-of-bone-in-limbs-a-prospective-single-center-single-arm-open-study-100565878","NCT06647901","Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study","Inclusion Criteria:\n\n1. . Aged 18-65.\n2. Biopsy confirmed giant cell tumor of bone.\n3. The lesions located in the limbs.\n4. This operation is the initial treatment.\n5. Denosumab and diphosphonates are not used before surgery.\n6. Planned operation is intralesional curettage and filling bone defects with bone cement.\n7. Preoperative bone scan and thin layer (layer thickness ≤3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without metastasis.\n8. Subjects fully understand the benefits and risks of this experiment and are still willing to participate and sign the informed consent.\n\nExclusion Criteria:\n\n1. . Known allergy to iodine contrast, indocyanine green or bone cement.\n2. . Severe hepatic and renal insufficiency.\n3. . During pregnancy or lactation.\n4. . Have other malignant tumors and are receiving related medical treatment.","65 Years",{"count":136,"type":20},45,[138,139],"PHASE1","PHASE2","ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.",[25],[143,144,145],"ICG","Giant cell tumor of bone","curettage","2024-10-16",{"date":148,"type":36},"2024-10-18",{"date":150,"type":36},"2024-08-23",{"date":152,"type":20},"2028-08-31",{"name":154,"class":43},"Tang Xiaodong",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":55,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":44},"100501777","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-narlumosbart-jmt103-in-patients-with-giant-cell-tumor-of-bone-100501777","NCT05813665","A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone","A Multi-center, Randomized, Double-blind, Active-controlled, Phase Ⅲ Study to Evaluate Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone","Inclusion Criteria:\n\n1. Fully informed and signed informed consent;\n2. Male or female adults aged ≥ 18 years or skeletally mature adolescents must weigh at least 45 kg and ≥ 12 years of age;\n3. Pathologically confirmed giant cell tumor of bone that is surgically unresectable or for which the planned surgery is associated with functional compromise or morbidity;\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Previous or ongoing osteomyelitis or osteonecrosis of the jaw, non-healed dental\u002Foral surgery, active dental or jaw condition requiring oral surgery, planned invasive dental procedure during the study;\n2. Known or suspected diagnosis of other giant cell-rich tumors, brown cell tumor of bone, or Paget's disease;\n3. Known diagnosis of malignancy within the past 5 years, except for definitively treated superficial basal cell carcinoma or cervical carcinoma in situ;\n4. Bone metabolic disease including hypo-\u002Fhyperparathyroidism, hypo-\u002Fhyperthyroidism (except for no need treatment subclinical hypothyroidism), hypopituitarism, hyperprolactinemia, Cushing's syndrome, acromegaly, etc.;\n5. Active infections requiring systematic treatment within 7 days prior to randomization;\n6. Known human immunodeficiency virus (HIV), syphilis infections or viral hepatitis;\n7. Current receiving other anti-tumor therapy (such as radiation, chemotherapy, or embolization, etc.);\n8. Concurrent bisphosphonate treatment;\n9. Use of anti-receptor activator of nuclear factor-κB ligand (RANKL) antibody within six months prior to screening, or no response to previous RANKL antibody treatment;\n10. Known allergic\u002Fhypersensitive reaction to JMT103, positive control drug, calcium and vitamin D;\n11. Pregnant or lactating females; For those of child bearing potential, refusal to use effective contraception methods from signing informed consent to 6 months after last administration.","12 Years",{"count":164,"type":20},146,[57],"This is a phase Ⅲ, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of narlumosbart (JMT103) in patients with unresectable or surgically difficult giant cell tumor of bone (GCTB). This clinical trial study hypothesizes narlumosbart administration groups are not inferior to active control administration groups.",[25],[25],"NOT_YET_RECRUITING","2023-04-16",{"date":172,"type":36},"2023-04-19",{"date":174,"type":20},"2023-04",{"date":176,"type":20},"2028-09",{"name":178,"class":179},"Shanghai JMT-Bio Inc.","INDUSTRY",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":55,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100485018","phase-2-zoledronic-acid-loaded-bone-cement-as-a-local-adjuvant-therapy-for-giant-cell-bone-tumor-after-intralesional-curettage-100485018","NCT05595603","Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage","Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage: a Prospective, Multicenter, Single Blinded, Randomized Control Trial.","Inclusion Criteria:\n\n* patients with primary resectable GCT of bone\n* lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal\n* no previous systemic bisphosphonate or denosumab therapy\n* with expected longer than 18 months of survival time\n* sign the informed consent form\n\nExclusion Criteria:\n\n* patients with recurrent GCT or extensive GCT which is impossible or inappropriate to use curettage surgery due to its \"unresectable\" nature.\n* conduct unexpected surgery at other center\n* the primary goal for surgery is revision\n* patient conduct en-bloc\u002Fwide resection instead of curettage surgery\n* patient can not conduct self-assessment during follow up\n* difficulty in complete postoperative follow-up\n* previous use of bisphosphonate\u002FZOL or denosumab drug\n* patients have participated in similar research projects\n* refused to sign informed consent",{"count":188,"type":20},153,[139],"The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).",[25],[193],"Zoledronic Acid, intralesional curettage","2023-03-13",{"date":196,"type":36},"2023-03-15",{"date":198,"type":20},"2023-03",{"date":200,"type":20},"2026-12-01",{"name":202,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]